Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 5,500 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 5,500 shares of the business's stock in a transaction dated Friday, April 4th. The shares were purchased at an average cost of $8.73 per share, with a total value of $48,015.00. Following the acquisition, the chief executive officer now owns 5,558,002 shares in the company, valued at $48,521,357.46. This trade represents a 0.10 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Monday, April 7th, Snehal Patel purchased 3,600 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.10 per share, for a total transaction of $32,760.00.
• On Friday, January 10th, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $12.51 per share, for a total transaction of $31,275.00.
• On Tuesday, January 7th, Snehal Patel acquired 1,800 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $13.75 per share, for a total transaction of $24,750.00.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI traded up $0.54 during mid-day trading on Friday, reaching $9.86. 35,240 shares of the company's stock were exchanged, compared to its average volume of 42,692. The business's fifty day moving average price is $11.21 and its 200-day moving average price is $12.54. Greenwich LifeSciences, Inc. has a twelve month low of $8.06 and a twelve month high of $18.75. The firm has a market capitalization of $129.61 million, a price-to-earnings ratio of -12.32 and a beta of 1.76.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Hedge Funds Weigh In On Greenwich LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after buying an additional 1,008 shares during the last quarter. Barclays PLC lifted its stake in Greenwich LifeSciences by 12.7% in the fourth quarter. Barclays PLC now owns 9,648 shares of the company's stock valued at $108,000 after buying an additional 1,088 shares during the period. GAMMA Investing LLC bought a new position in shares of Greenwich LifeSciences during the 1st quarter worth approximately $126,000. Bank of America Corp DE increased its stake in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after purchasing an additional 3,005 shares in the last quarter. 4.16% of the stock is owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.